Specify a stock or a cryptocurrency in the search bar to get a summary
Day One Biopharmaceuticals Inc
DAWNDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. Address: 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
Analytics
WallStreet Target Price
37 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures DAWN
Dividend Analytics DAWN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History DAWN
Stock Valuation DAWN
Financials DAWN
Results | 2019 | Dynamics |